On April 12th, 2022 NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is delighted to reported that over the course of the last two quarters it has taken the next steps forward in its commitment to developing next generation pharmaceuticals by forming exclusive licensing agreements with Radiopharm Theranostics (ASX: RAD) and Full Life Technologies (HK) Ltd (Press release, NanoMab, APR 12, 2022, View Source [SID1234645316]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreements grant RAD full rights to develop three of NanoMab’s single-domain antibody assets: NM-02, NM-03, and NM-04; respectively targeting HER-2 (breast cancer), TROP-2 (triple negative breast cancer), and PTK7 (multiple solid tumours) biomarkers. RAD is an ASX-listed company led by a strong global team with world-class experience, who aim to develop radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. RAD is the latest venture of Australian bioentrepreneur, Paul Hopper, who is behind numerous successful companies developing oncology drugs.
Additionally, an agreement issuing the full IP right to develop NM-05 (sdAb targeting FAP) has been established with Full-Life Technologies (HK) Ltd. Full-life is a global nuclear health company seeking to tackle two core issues experienced in the radiopharmaceuticals sector; the ability to produce primarily alpha- and beta- medical radioisotopes in quantity, and the development of an innovative translational research platform for Targeted-Radiotherapy.
NanoMab believes these exclusive licensing agreements have formalised the strategic collaborations between the respective parties, which will speed up the development and commercialisation of our unique platform of immuno-oncology theranostic drugs to aid patients in the battle against aggressive cancers.